Nesfatin-1 is an 82-residue anorexigenic peptide cleaved from the precursor nucleobindin-2. What distinguished it when characterised was that its food-intake-reducing effect does not require the leptin receptor, placing it outside the best-mapped pathway of energy balance rather than within it. This is the human sequence, and the human peptide's main research role differs from the rodent forms. Circulating NUCB2/nesfatin-1 has been measured in human cohorts and examined in relation to metabolic status, which makes a well-defined human standard the limiting reagent for that work: immunoassay values are only comparable between studies if calibrated against the correct species sequence, and antibody cross-reactivity between human and rodent forms cannot be assumed. The peptide is also expressed well beyond the hypothalamus, in stomach and adipose tissue among other sites, so human tissue and cell-line studies frequently need the homologous peptide rather than a rodent surrogate. At over eighty residues this is a large peptide, and handling differs from that of short signalling peptides. Adsorption to plastic, solubility at working concentration and freeze-thaw stability all matter more here, and concentration should be verified rather than assumed from the vial label when the value feeds into a standard curve. | 